+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmacogenomics Market by Therapeutic Area (Cardiology, Infectious Diseases, Neurology), Product (Consumables, Services, Software and Platforms), Technology, End User, Test Type, Biomarker Type - Global Forecast 2025-2030- Product Image
Pharmacogenomics Market by Therapeutic Area (Cardiology, Infectious Diseases, Neurology), Product (Consumables, Services, Software and Platforms), Technology, End User, Test Type, Biomarker Type - Global Forecast 2025-2030- Product Image
Sale

Pharmacogenomics Market by Therapeutic Area (Cardiology, Infectious Diseases, Neurology), Product (Consumables, Services, Software and Platforms), Technology, End User, Test Type, Biomarker Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5716074
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The pharmacogenomics market is rapidly transforming healthcare by enabling personalized treatment strategies grounded in genetic insights. As organizations increasingly prioritize precision medicine, the integration of advanced genomics technologies and analytics is redefining drug development and patient care pathways for senior decision-makers.

Market Snapshot: Pharmacogenomics Market Size and Growth Overview

The pharmacogenomics market grew from USD 4.48 billion in 2024 to USD 4.98 billion in 2025. It is expected to continue growing at a CAGR of 10.59%, reaching USD 8.21 billion by 2030. This trajectory demonstrates sustained momentum as the field becomes embedded within standard healthcare operations, marked by increasing adoption among pharma and diagnostic sectors alike.

Scope & Segmentation: Expansive Landscape of Pharmacogenomics

This report provides in-depth analysis across market segments and sub-regions, reflecting the diverse opportunities within pharmacogenomics:

  • Therapeutic Areas: Cardiology, Infectious Diseases, Neurology, Oncology
  • Product Portfolio: Consumables (kits, reagents), Services (clinical and research), Software and Platforms (data analysis, e-clinical solutions, reporting/interpretation)
  • Technology Platforms: Microarray (expression arrays, SNP arrays), Polymerase Chain Reaction (digital PCR, real-time PCR), Sequencing (next-generation, Sanger sequencing)
  • End Users: Diagnostic laboratories (hospital-based and reference), Hospitals, Pharmaceutical companies, Research organizations
  • Test Types: Genotyping, Phenotyping
  • Biomarker Types: Germline, Somatic
  • Geographical Coverage: Americas (including major states and countries), Europe, Middle East & Africa, Asia-Pacific

Profiled companies include Thermo Fisher Scientific Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, QIAGEN N.V., PerkinElmer, Inc., and additional leaders shaping the sector.

Key Takeaways: Strategic Insights for Decision-Makers

  • Integration of pharmacogenomics into mainstream clinical care is accelerating, driven by value-based healthcare shifts and regulatory developments.
  • Collaborations between pharmaceutical, diagnostic, and technology companies are raising operational efficiency and expanding access to patient-centric solutions.
  • Data-driven technologies such as artificial intelligence and machine learning are enhancing the discovery and interpretation of clinically actionable biomarkers.
  • Regional advancement is defined by varying access, regulatory harmonization, and public-private investment, with Asia-Pacific emerging as a high-growth area for pharmacogenomic solutions.
  • Flexible product offerings and modular service models allow end users to tailor deployments for both high-throughput environments and targeted clinical needs.
  • Competitive dynamics increasingly favor organizations able to balance innovation, strategic partnerships, and responsiveness to evolving payer and regulatory expectations.

Tariff Impact: Navigating U.S. Policy Changes in the Pharmacogenomics Supply Chain

Recent adjustments to U.S. tariffs on imported reagents, instruments, and consumables have reshaped procurement and production strategies within the pharmacogenomics value chain. Organizations are reevaluating sourcing, with increased investment in domestic manufacturing and process optimization to help sustain pricing competitiveness. These policies have resulted in longer lead times and greater emphasis on automation and efficiency to offset rising operational costs.

Pharmacogenomics Market Methodology & Data Sources

This research employs a robust, multi-source approach. Primary data stemmed from detailed interviews with stakeholders in laboratories, pharmaceuticals, technology vendors, and regulatory agencies. Secondary sources included peer-reviewed literature, regulatory filings, industry reports, and white papers. Findings were validated through scenario modeling and expert review to ensure the accuracy and relevance of insights for the pharmacogenomics market.

Why This Report Matters for Senior Leaders

  • Enables informed investment and partnership decisions aligned with current and future regional and technological trends.
  • Provides actionable strategic direction for product and platform development, regulatory navigation, and operational resilience under shifting economic policies.
  • Facilitates a deeper understanding of competitive moves, allowing organizations to effectively prioritize and allocate resources within the dynamic pharmacogenomics landscape.

Conclusion: Strategic Imperatives in Pharmacogenomics

Pharmacogenomics is positioned for substantial growth as advancements in technology and changing regulatory frameworks reshape the market. Senior decision-makers equipped with this report can proactively align their initiatives for resilience and sustainable value in a rapidly evolving landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of AI-driven genotype analysis platforms for personalized drug prescribing
5.2. Expansion of point-of-care pharmacogenomic testing with rapid turnaround in clinical settings
5.3. Shift in payer and reimbursement policies supporting companion diagnostic coverage
5.4. Adoption of multi-gene pharmacogenomic panels for adverse drug reaction risk assessment
5.5. Investment surge in biopharmaceutical R&D leveraging pharmacogenomic biomarkers for targeted therapies
5.6. Regulatory harmonization initiatives for standardized pharmacogenomic data reporting and interpretation
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pharmacogenomics Market, by Therapeutic Area
8.1. Introduction
8.2. Cardiology
8.3. Infectious Diseases
8.4. Neurology
8.5. Oncology
9. Pharmacogenomics Market, by Product
9.1. Introduction
9.2. Consumables
9.2.1. Kits
9.2.2. Reagents
9.3. Services
9.3.1. Clinical Services
9.3.2. Research Services
9.4. Software And Platforms
9.4.1. Data Analysis
9.4.2. E-Clinical Solutions
9.4.3. Reporting And Interpretation
10. Pharmacogenomics Market, by Technology
10.1. Introduction
10.2. Microarray
10.2.1. Expression Arrays
10.2.2. SNP Arrays
10.3. Polymerase Chain Reaction
10.3.1. Digital PCR
10.3.2. Real-Time PCR
10.4. Sequencing
10.4.1. Next-Generation Sequencing
10.4.2. Sanger Sequencing
11. Pharmacogenomics Market, by End User
11.1. Introduction
11.2. Diagnostic Laboratories
11.2.1. Hospital-Based Laboratories
11.2.2. Reference Laboratories
11.3. Hospitals
11.4. Pharmaceutical Companies
11.5. Research Organizations
12. Pharmacogenomics Market, by Test Type
12.1. Introduction
12.2. Genotyping
12.3. Phenotyping
13. Pharmacogenomics Market, by Biomarker Type
13.1. Introduction
13.2. Germline
13.3. Somatic
14. Americas Pharmacogenomics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Pharmacogenomics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Pharmacogenomics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Thermo Fisher Scientific Inc.
17.3.2. Illumina, Inc.
17.3.3. F. Hoffmann-La Roche Ltd
17.3.4. QIAGEN N.V.
17.3.5. PerkinElmer, Inc.
17.3.6. Agilent Technologies, Inc.
17.3.7. Bio-Rad Laboratories, Inc.
17.3.8. Myriad Genetics, Inc.
17.3.9. Invitae Corporation
17.3.10. Natera, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PHARMACOGENOMICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. PHARMACOGENOMICS MARKET: RESEARCHAI
FIGURE 28. PHARMACOGENOMICS MARKET: RESEARCHSTATISTICS
FIGURE 29. PHARMACOGENOMICS MARKET: RESEARCHCONTACTS
FIGURE 30. PHARMACOGENOMICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PHARMACOGENOMICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY KITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY RESEARCH SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY RESEARCH SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY E-CLINICAL SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY E-CLINICAL SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REPORTING AND INTERPRETATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REPORTING AND INTERPRETATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY EXPRESSION ARRAYS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY EXPRESSION ARRAYS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SNP ARRAYS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SNP ARRAYS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GENOTYPING, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GENOTYPING, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PHENOTYPING, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PHENOTYPING, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GERMLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GERMLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOMATIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOMATIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 157. CANADA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 158. CANADA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 159. CANADA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 160. CANADA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 161. CANADA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 162. CANADA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 163. CANADA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 164. CANADA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 165. CANADA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2024 (USD MILLION)
TABLE 166. CANADA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2025-2030 (USD MILLION)
TABLE 167. CANADA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 168. CANADA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 169. CANADA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 170. CANADA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 171. CANADA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 172. CANADA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 173. CANADA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 174. CANADA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 175. CANADA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. CANADA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. CANADA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 178. CANADA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 179. CANADA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 180. CANADA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 181. CANADA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 182. CANADA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 183. MEXICO PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 184. MEXICO PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 185. MEXICO PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 186. MEXICO PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 187. MEXICO PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 188. MEXICO PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 189. MEXICO PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 190. MEXICO PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 191. MEXICO PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2024 (USD MILLION)
TABLE 192. MEXICO PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2025-2030 (USD MILLION)
TABLE 193. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 194. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 195. MEXICO PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 196. MEXICO PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 197. MEXICO PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 198. MEXICO PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 199. MEXICO PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 200. MEXICO PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 201. MEXICO PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. MEXICO PHARMACOGENOMICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. MEXICO PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 204. MEXICO PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 205. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 206. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 207. MEXICO PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 208. MEXICO PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 311. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 312. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 314. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 315. GERMANY PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 316. GERMANY PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 317. GERMANY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 318. GERMANY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 319. GERMANY PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 320. GERMANY PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 321. GERMANY PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 322. GERMANY PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 323. GERMANY PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2024 (USD MILLION)
TABLE 324. GERMANY PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2025-2030 (USD MILLION)
TABLE 325. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 326. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 327. GERMANY PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
TABLE 328. GERMANY PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2025-2030 (USD MILLION)
TABLE 329. GERMANY PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
TABLE 330. GERMANY PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2030 (USD MILLION)
TABLE 331. GERMANY PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 332. GERMANY PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 333. GERMANY PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 334. GERMANY PHARMACOGENOMICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 335. GERMANY PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
TABLE 336. GERMANY PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2030 (USD MILLION)
TABLE 337. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 338. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 339. GERMANY PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
TABLE 340. GERMANY PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
TABLE 341. FRANCE PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 342. FRANCE PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 343. FRANCE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 344. FRANCE PHARMACOGENOMICS MARKET SIZE, B

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Pharmacogenomics market report include:
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • QIAGEN N.V.
  • PerkinElmer, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Invitae Corporation
  • Natera, Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.98 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.21 Billion
Compound Annual Growth Rate10.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Pharmacogenomics Services Market by Genetic Testing Technology, Test Type, Application Areas, Pharmaceutical Development, Technology Platforms, Laboratory Automation - Global Forecast to 2030 - Product Image

Pharmacogenomics Services Market by Genetic Testing Technology, Test Type, Application Areas, Pharmaceutical Development, Technology Platforms, Laboratory Automation - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Predictive Genetics Market by Technology (Microarray, Next Generation Sequencing, Polymerase Chain Reaction), Test Type (Cancer Screening, Carrier Screening, Pharmacogenomics), Application, End User, Product Type - Global Forecast 2025-2030 - Product Image

Predictive Genetics Market by Technology (Microarray, Next Generation Sequencing, Polymerase Chain Reaction), Test Type (Cancer Screening, Carrier Screening, Pharmacogenomics), Application, End User, Product Type - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Pharmacogenomics Technology Market Size, Share & Trends Analysis Report by Therapeutic Area (Neurological Disorders, Cardiovascular Disease), Technology (PCR, in-situ Hybridization), Region, with Growth Forecasts, 2025-2030 - Product Image

Pharmacogenomics Technology Market Size, Share & Trends Analysis Report by Therapeutic Area (Neurological Disorders, Cardiovascular Disease), Technology (PCR, in-situ Hybridization), Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Pharmacogenomics Market Report by Technology, Application, End User, and Region 2024-2032 - Product Image

Pharmacogenomics Market Report by Technology, Application, End User, and Region 2024-2032

  • Report
  • 136 Pages
  • Global
From
Pharmacogenomics Market by Technology, by Application, by End-users, and by Region - Product Image

Pharmacogenomics Market by Technology, by Application, by End-users, and by Region

  • Report
  • 200 Pages
  • Global
From

About the Market

Pharmacogenomics is a field of genomics that studies the relationship between an individual's genetic makeup and their response to drugs. It is used to develop personalized medicine, which is tailored to an individual's genetic profile. This field of genomics has the potential to revolutionize the way drugs are developed and prescribed, as it can help to identify which drugs are most effective for a particular patient. It can also help to reduce the risk of adverse drug reactions, as well as reduce the cost of drug development. Pharmacogenomics is a rapidly growing field, with many companies investing in research and development. Examples of companies in the market include 23andMe, Genomics England, and Illumina. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.